Understanding how a protein called Sox9 affects lung scarring in pulmonary fibrosis
Sox9 Regulation of Fibroblast Activation and Pulmonary Fibrosis
This research explores how a protein called Sox9 contributes to the lung scarring seen in people with idiopathic pulmonary fibrosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11134445 on NIH RePORTER |
What this research studies
Idiopathic pulmonary fibrosis (IPF) is a serious lung disease where scar tissue builds up, making it progressively harder to breathe. This scarring happens because certain cells in the lung, called fibroblasts, become overactive and create too much scar tissue. Scientists are working to understand the exact signals that cause these fibroblasts to become active and form scars. This project focuses on a protein named Sox9, which appears to play a key role in activating these scar-forming cells. By understanding how Sox9 works, we hope to find new ways to stop or slow down the progression of lung scarring in IPF.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients, but future studies stemming from this work may seek individuals with idiopathic pulmonary fibrosis.
Not a fit: Patients without idiopathic pulmonary fibrosis or similar fibrotic lung conditions would likely not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that target Sox9 to prevent or reduce lung scarring in patients with idiopathic pulmonary fibrosis.
How similar studies have performed: While the role of Sox9 in adult fibrotic lung diseases is poorly studied, new findings from this team and a recent study on liver fibrosis suggest Sox9's importance in scarring.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Madala, Satish K — University of Cincinnati
- Study coordinator: Madala, Satish K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.